Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 156 articles:
HTML format
Text format



Single Articles


    August 2017
  1. HE Q, Bi X, Ren C, Wang Y, et al
    Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.
    Anticancer Res. 2017;37:4711-4716.
    PubMed     Text format     Abstract available


  2. WONG W, Sun P, Mu Z, Liu J, et al
    Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4687-4691.
    PubMed     Text format     Abstract available


  3. YANG Y, Sun N, Sun P, Zhang L, et al
    Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
    Anticancer Res. 2017;37:4681-4686.
    PubMed     Text format     Abstract available


  4. WANG F, Lu J, Li S, Huo X, et al
    Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
    Anticancer Res. 2017;37:4515-4522.
    PubMed     Text format     Abstract available


  5. YANG F, Gu Y, Zhao Z, Huang J, et al
    NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:4405-4414.
    PubMed     Text format     Abstract available


  6. ZHAO Z, Cheng S, Zabkiewicz C, Chen J, et al
    Reduced Expression of RanBPM Is Associated with Poorer Survival from Lung Cancer and Increased Proliferation and Invasion of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:4389-4397.
    PubMed     Text format     Abstract available


  7. FLAMINI V, Jiang WG, Cui Y
    Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4319-4327.
    PubMed     Text format     Abstract available


  8. YU Z, Sanders AJ, Owen S, Cheng S, et al
    Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells.
    Anticancer Res. 2017;37:4277-4283.
    PubMed     Text format     Abstract available


  9. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4223-4228.
    PubMed     Text format     Abstract available


  10. TAMIYA A, Tamiya M, Nishihara T, Shiroyama T, et al
    Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Anticancer Res. 2017;37:4177-4182.
    PubMed     Text format     Abstract available


    July 2017
  11. YOTSUMOTO F, Fukagawa S, Miyata K, Nam SO, et al
    HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M.
    Anticancer Res. 2017;37:3825-3831.
    PubMed     Text format     Abstract available


  12. NAKAO M, Muramatsu H, Kagawa Y, Suzuki Y, et al
    Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations.
    Anticancer Res. 2017;37:3781-3786.
    PubMed     Text format     Abstract available


  13. BANNA GL, Parra HJS, Castaing M, Dieci MV, et al
    Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:3723-3728.
    PubMed     Text format     Abstract available


  14. SHEN TC, Hsia TC, Chao CY, Chen WC, et al
    The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer.
    Anticancer Res. 2017;37:3563-3567.
    PubMed     Text format     Abstract available


  15. PANCEWICZ-WOJTKIEWICZ J, Bernatowicz PL
    The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:3543-3546.
    PubMed     Text format     Abstract available


  16. OTSUKA T, Nojiri T, Minami S, Hosoda H, et al
    Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
    Anticancer Res. 2017;37:3505-3512.
    PubMed     Text format     Abstract available


    June 2017
  17. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer.
    Anticancer Res. 2017;37:3307-3309.
    PubMed     Text format     Abstract available


  18. NAKAMICHI S, Seike M, Miyanaga A, Chiba M, et al
    RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients.
    Anticancer Res. 2017;37:3295-3299.
    PubMed     Text format     Abstract available


  19. MUTO S, Takagi H, Owada Y, Inoue T, et al
    Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:3169-3174.
    PubMed     Text format     Abstract available


  20. WANG W, Zhong W, Chen C, Meng Q, et al
    Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
    Anticancer Res. 2017;37:3151-3155.
    PubMed     Text format     Abstract available


    May 2017
  21. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.
    Anticancer Res. 2017;37:2721-2725.
    PubMed     Text format     Abstract available


  22. SHOJI F, Toyokawa G, Harada N, Itoh S, et al
    Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation.
    Anticancer Res. 2017;37:2619-2623.
    PubMed     Text format     Abstract available


  23. JANSSEN S, VAN Oorschot B, Kasmann L, Schild SE, et al
    Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer.
    Anticancer Res. 2017;37:2537-2540.
    PubMed     Text format     Abstract available


  24. LIU D, Nakashima N, Nakano J, Tarumi S, et al
    Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Anticancer Res. 2017;37:2501-2507.
    PubMed     Text format     Abstract available


  25. DE MARINIS F, Bidoli P, Luciani A, Amoroso D, et al
    EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2457-2464.
    PubMed     Text format     Abstract available


  26. CHUANG CL, Wang CH, Hsu CH, Hsiao CL, et al
    Contribution of Double-strand Break Repair Gene Nijmegen Breakage Syndrome 1 Genotypes, Gender Difference and Smoking Status to Taiwanese Lung Cancer.
    Anticancer Res. 2017;37:2417-2423.
    PubMed     Text format     Abstract available


  27. LEE AY, Kim S, Lee S, Jiang HL, et al
    Knockdown of Importin 7 Inhibits Lung Tumorigenesis in K-rasLA1 Lung Cancer Mice.
    Anticancer Res. 2017;37:2381-2386.
    PubMed     Text format     Abstract available


  28. MASAGO K, Fujita S, Hata A, Okuda C, et al
    PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2269-2274.
    PubMed     Text format     Abstract available


  29. HAO C, Cui Y, Hu MU, Zhi X, et al
    OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:2245-2254.
    PubMed     Text format     Abstract available


  30. TOKUNAGA S, Nagano T, Kobayashi K, Katsurada M, et al
    Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
    Anticancer Res. 2017;37:2225-2231.
    PubMed     Text format     Abstract available


  31. AKAMINE T, Toyokawa G, Matsubara T, Kozuma Y, et al
    Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease.
    Anticancer Res. 2017;37:2735-2742.
    PubMed     Text format     Abstract available


  32. JINGU K, Matsuo Y, Onishi H, Yamamoto T, et al
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:2709-2713.
    PubMed     Text format     Abstract available


  33. MIYATA T, Oyama T, Yoshimatsu T, Higa H, et al
    The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.
    Anticancer Res. 2017;37:2541-2547.
    PubMed     Text format     Abstract available


  34. DORE-SAVARD L, Chen Z, Winnard PT Jr, Krishnamachary B, et al
    Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
    Anticancer Res. 2017;37:2195-2200.
    PubMed     Text format     Abstract available


    April 2017
  35. TSOUKALAS N, Aravantinou-Fatorou E, Tolia M, Giaginis C, et al
    Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1773-1778.
    PubMed     Text format     Abstract available


  36. OKAMOTO T, Kohno M, Ito K, Takada K, et al
    Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Anticancer Res. 2017;37:1729-1735.
    PubMed     Text format     Abstract available


  37. KAITO D, Iihara H, Funaguchi N, Endo J, et al
    Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.
    Anticancer Res. 2017;37:1965-1970.
    PubMed     Text format     Abstract available


  38. ABE S, Yamashita SI, Miyahara SO, Wakahara J, et al
    Prognostic Significance of BMI-1 But Not MEL-18 Expression in Pulmonary Squamous Cell Carcinoma.
    Anticancer Res. 2017;37:1923-1929.
    PubMed     Text format     Abstract available


    March 2017
  39. KASMANN L, Bolm L, Janssen S, Rades D, et al
    Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1535-1537.
    PubMed     Text format     Abstract available


  40. YOH K, Goto Y, Naito Y, Kishi K, et al
    Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2017;37:1507-1513.
    PubMed     Text format     Abstract available


  41. TOYOKAWA G, Takada K, Okamoto T, Kozuma Y, et al
    Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:1393-1401.
    PubMed     Text format     Abstract available


  42. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  43. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.
    Anticancer Res. 2017;37:1413-1416.
    PubMed     Text format     Abstract available


  44. BATTOLLA E, Canessa PA, Ferro P, Franceschini MC, et al
    Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Anticancer Res. 2017;37:1387-1391.
    PubMed     Text format     Abstract available


    February 2017
  45. SONE K, Oguri T, Nakao M, Kagawa Y, et al
    CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Anticancer Res. 2017;37:935-939.
    PubMed     Text format     Abstract available


  46. YAMASAKI M, Murakami I, Nakano K, Doi M, et al
    Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:923-928.
    PubMed     Text format     Abstract available


  47. TOYOKAWA G, Kozuma Y, Matsubara T, Haratake N, et al
    Radiological Features of the Surgically Resected Small-sized Small-cell Lung Cancer on Computed Tomography.
    Anticancer Res. 2017;37:877-881.
    PubMed     Text format     Abstract available


  48. TAKEDA K, Yamasaki A, Igishi T, Kawasaki Y, et al
    Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema.
    Anticancer Res. 2017;37:765-771.
    PubMed     Text format     Abstract available


  49. SHOJI F, Haratake N, Akamine T, Takamori S, et al
    The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:741-747.
    PubMed     Text format     Abstract available


  50. ISHIKURA N, Yanagisawa M, Noguchi-Sasaki M, Iwai T, et al
    Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Anticancer Res. 2017;37:623-629.
    PubMed     Text format     Abstract available


  51. SIRIMANGKALAKITTI N, Chamni S, Suwanborirux K, Chanvorachote P, et al
    Renieramycin M Attenuates Cancer Stem Cell-like Phenotypes in H460 Lung Cancer Cells.
    Anticancer Res. 2017;37:615-621.
    PubMed     Text format     Abstract available


  52. RAFEI H, El-Bahesh E, Finianos A, Nassereddine S, et al
    Immune-based Therapies for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:377-387.
    PubMed     Text format     Abstract available


  53. TANDBERG DJ, Holt T, Kelsey CR
    Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study.
    Anticancer Res. 2017;37:719-725.
    PubMed     Text format     Abstract available


  54. LIM YS, Cha W, Park MW, Jeong WJ, et al
    HIF1alpha in Tumorigenesis of Adenoid Cystic Carcinoma.
    Anticancer Res. 2017;37:599-606.
    PubMed     Text format     Abstract available


    January 2017
  55. CHUDASAMA D, Barr J, Beeson J, Beddows E, et al
    Detection of Circulating Tumour Cells and Survival of Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:169-173.
    PubMed     Text format     Abstract available


  56. SUZAWA K, Shien K, Peng H, Sakaguchi M, et al
    Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.
    Anticancer Res. 2017;37:301-307.
    PubMed     Text format     Abstract available


  57. FUJIYOSHI K, Yamamoto G, Takenoya T, Takahashi A, et al
    Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Anticancer Res. 2017;37:239-247.
    PubMed     Text format     Abstract available


  58. YURUGI Y, Wakahara M, Matsuoka Y, Sakabe T, et al
    Podoplanin Expression in Cancer-associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung.
    Anticancer Res. 2017;37:207-213.
    PubMed     Text format     Abstract available


  59. PASQUALETTI F, Montrone S, Vivaldi C, Zani M, et al
    Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:315-319.
    PubMed     Text format     Abstract available


  60. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models.
    Anticancer Res. 2017;37:57-60.
    PubMed     Text format     Abstract available


    December 2016
  61. ISLA D, Felip E, Vinolas N, Provencio M, et al
    Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.
    Anticancer Res. 2016;36:6647-6653.
    PubMed     Text format     Abstract available


  62. KAIRA K, Higuchi T, Sunaga N, Arisaka Y, et al
    Usefulness of 18F-alpha-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.
    Anticancer Res. 2016;36:6481-6490.
    PubMed     Text format     Abstract available


  63. PINKHIEN T, Maiuthed A, Chamni S, Suwanborirux K, et al
    Bishydroquinone Renieramycin M Induces Apoptosis of Human Lung Cancer Cells Through a Mitochondria-dependent Pathway.
    Anticancer Res. 2016;36:6327-6333.
    PubMed     Text format     Abstract available


  64. YOSHIDA T, Okamoto T, Yano T, Takada K, et al
    Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:6319-6326.
    PubMed     Text format     Abstract available


  65. GRIDELLI C, Chella A, Valmadre G, Allegrini G, et al
    Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.
    Anticancer Res. 2016;36:6535-6540.
    PubMed     Text format     Abstract available


  66. CHECK JH, Check D, Wilson C, Lofberg P, et al
    Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
    Anticancer Res. 2016;36:6511-6513.
    PubMed     Text format     Abstract available


  67. SUNDARAM S, Yan L
    High-fat Diet Enhances Mammary Tumorigenesis and Pulmonary Metastasis and Alters Inflammatory and Angiogenic Profiles in MMTV-PyMT Mice.
    Anticancer Res. 2016;36:6279-6287.
    PubMed     Text format     Abstract available


  68. OKAZAKI I, Ishikawa S, Ando W, Sohara Y, et al
    Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens.
    Anticancer Res. 2016;36:6207-6224.
    PubMed     Text format     Abstract available


    November 2016
  69. HSIA TC, Yu CC, Hsiao YT, Wu SH, et al
    Cantharidin Impairs Cell Migration and Invasion of Human Lung Cancer NCI-H460 Cells via UPA and MAPK Signaling Pathways.
    Anticancer Res. 2016;36:5989-5997.
    PubMed     Text format     Abstract available


  70. YASUKAWA M, Nakazawa T, Kawaguchi T, Kawai N, et al
    Minodronic Acid in Combination with gammadeltaT Cells Induces Apoptosis of Non-small Cell Lung Carcinoma Cell Lines.
    Anticancer Res. 2016;36:5883-5886.
    PubMed     Text format     Abstract available


  71. CHANVORACHOTE P, Chamni S, Ninsontia C, Phiboonchaiyanan PP, et al
    Potential Anti-metastasis Natural Compounds for Lung Cancer.
    Anticancer Res. 2016;36:5707-5717.
    PubMed     Text format     Abstract available


  72. WATARAI H, Okada M, Kuramoto K, Takeda H, et al
    Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.
    Anticancer Res. 2016;36:6083-6092.
    PubMed     Text format     Abstract available


  73. YE X, Zhou Q, Matsumoto Y, Moriyama M, et al
    Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma.
    Anticancer Res. 2016;36:6021-6029.
    PubMed     Text format     Abstract available


  74. AMBROSIO R, Ombra MN, Gridelli C, Picariello G, et al
    Isoflavone Extracts Enhance the Effect of Epidermal Growth Factor Receptor Inhibitors in NSCLC Cell Lines.
    Anticancer Res. 2016;36:5827-5833.
    PubMed     Text format     Abstract available


    October 2016
  75. KARZIJN R, Alberts L, Kelder JC, Hofman FN, et al
    Post-treatment Surveillance for Stage I and II Non-small Cell Lung Cancer: Impact on Clinical Outcome.
    Anticancer Res. 2016;36:5413-5418.
    PubMed     Text format     Abstract available


  76. KOYI H, Hillerdal G, Kolbeck KG, Brodin D, et al
    Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice.
    Anticancer Res. 2016;36:5397-5402.
    PubMed     Text format     Abstract available


  77. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


  78. MAEBAYASHI T, Ishibashi N, Aizawa T, Sakaguchi M, et al
    Radiation Pneumonitis Changes over Time after Stereotactic Body Radiation Therapy for Lung Tumors: Post-treatment Cavity (Sunny-side-up Egg-like) Changes.
    Anticancer Res. 2016;36:5563-5570.
    PubMed     Text format     Abstract available


    September 2016
  79. INOMATA M, Shimokawa K, Tokui K, Taka C, et al
    Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:4951-4.
    PubMed     Text format     Abstract available


  80. SCHMID S, LE UT, Haager B, Mayer O, et al
    Local Concentrations of CC-Chemokine-Ligand 18 Correlate with Tumor Size in Non-small Cell Lung Cancer and Are Elevated in Lymph Node-positive Disease.
    Anticancer Res. 2016;36:4667-71.
    PubMed     Text format     Abstract available


  81. MATSUOKA Y, Yurugi Y, Takagi Y, Wakahara M, et al
    Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring </=3 cm.
    Anticancer Res. 2016;36:4923-30.
    PubMed     Text format     Abstract available


  82. TOYOKAWA G, Taguchi K, Edagawa M, Shimamatsu S, et al
    The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
    Anticancer Res. 2016;36:4841-6.
    PubMed     Text format     Abstract available


  83. VAN DER MEER FS, Schramel FM, VAN Vulpen M, El Sharouni SY, et al
    Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III.
    Anticancer Res. 2016;36:4673-6.
    PubMed     Text format     Abstract available


    August 2016
  84. TOYOKAWA G, Takada K, Haratake N, Takamori S, et al
    Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
    Anticancer Res. 2016;36:4329-36.
    PubMed     Text format     Abstract available


  85. OOI H, Chen CY, Hsiao YC, Huang WS, et al
    Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis.
    Anticancer Res. 2016;36:4313-20.
    PubMed     Text format     Abstract available


  86. DAVIES RS, Nelmes DJ, Butler R, Lester JF, et al
    Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?
    Anticancer Res. 2016;36:4267-71.
    PubMed     Text format     Abstract available


  87. KASMANN L, Janssen S, Rades D
    Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer.
    Anticancer Res. 2016;36:4177-80.
    PubMed     Text format     Abstract available


  88. SILVONIEMI M, Vasankari T, Loyttyniemi E, Valtonen M, et al
    Symptom Assessment for Patients with Non-small Cell Lung Cancer Scheduled for Chemotherapy.
    Anticancer Res. 2016;36:4123-8.
    PubMed     Text format     Abstract available



  89. Advances in Respiratory Cancerogenesis.
    Anticancer Res. 2016;36:4376.
    PubMed     Text format    


  90. URAMOTO H, Nakajima Y, Kinoshita H, Akiyama H, et al
    Equivalent Outcome of Patients with Locally Advanced NSCLC Treated with Salvage Surgery Compared to Induction Chemotherapy Followed by Surgical Resection.
    Anticancer Res. 2016;36:4243-7.
    PubMed     Text format     Abstract available


  91. MAYS AC, Feng X, Browne JD, Sullivan CA, et al
    Chemokine and Chemokine Receptor Profiles in Metastatic Salivary Adenoid Cystic Carcinoma.
    Anticancer Res. 2016;36:4013-8.
    PubMed     Text format     Abstract available


  92. TOME Y, Yano S, Sugimoto N, Mii S, et al
    Use of alphav Integrin Linked to Green Fluorescent Protein in Osteosarcoma Cells and Confocal Microscopy to Image Molecular Dynamics During Lung Metastasis in Nude Mice.
    Anticancer Res. 2016;36:3811-6.
    PubMed     Text format     Abstract available


    July 2016
  93. INUI T, Amitani H, Kubo K, Kuchiike D, et al
    Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
    Anticancer Res. 2016;36:3767-70.
    PubMed     Text format     Abstract available


  94. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Text format     Abstract available


  95. KASMANN L, Janssen S, Rades D
    Prognostic Factors Including the Expression of Thyroid Transcription Factor 1 (TTF1) in Patients Irradiated for Limited-disease Small Cell Lung Cancer.
    Anticancer Res. 2016;36:3499-503.
    PubMed     Text format     Abstract available


  96. TAKADA K, Toyokawa G, Okamoto T, Akamine T, et al
    An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
    Anticancer Res. 2016;36:3409-12.
    PubMed     Text format     Abstract available


  97. HOLZER TR, Fulford AD, Reising LO, Nedderman DM, et al
    Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
    Anticancer Res. 2016;36:3277-88.
    PubMed     Text format     Abstract available


  98. OISHI S, Kudaka W, Toita T, Ariga T, et al
    Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.
    Anticancer Res. 2016;36:3471-5.
    PubMed     Text format     Abstract available


  99. MATSUI T, Nagata N, Hirata K, Okazaki S, et al
    Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
    Anticancer Res. 2016;36:3437-43.
    PubMed     Text format     Abstract available


    June 2016
  100. TAMIYA M, Tamiya A, Yasue T, Nakao K, et al
    Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
    Anticancer Res. 2016;36:2939-44.
    PubMed     Text format     Abstract available


  101. YAMADA K, Azuma K, Takeshita M, Uchino J, et al
    Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
    Anticancer Res. 2016;36:2881-7.
    PubMed     Text format     Abstract available


  102. OKAMOTO T, Kitahara H, Shimamatsu S, Katsura M, et al
    Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
    Anticancer Res. 2016;36:3057-63.
    PubMed     Text format     Abstract available


    May 2016
  103. URAMOTO H, Iijima Y, Nakajima Y, Kinoshita H, et al
    Accurate Diagnosis of Aortic Invasion in Patients with Lung Cancer.
    Anticancer Res. 2016;36:2391-5.
    PubMed     Text format     Abstract available


  104. URAMOTO H, Nakajima Y, Kinoshita H
    Is the Isolated Pericardial Fat Pad Sufficient to Cover the Bronchial Stump and Separate the Pulmonary Artery in Order to Prevent Bronchopleural Fistula in Patients with Lung Cancer?
    Anticancer Res. 2016;36:2385-9.
    PubMed     Text format     Abstract available


  105. NICOS M, Krawczyk P, Powrozek T, Szudy P, et al
    PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:2243-9.
    PubMed     Text format     Abstract available


  106. SU JM, Hsu YY, Lin P, Chang H, et al
    Nuclear Accumulation of Heat-shock Protein 90 Is Associated with Poor Survival and Metastasis in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:2197-203.
    PubMed     Text format     Abstract available


  107. ROCCO G, Petitti T, Martucci N, Piccirillo MC, et al
    Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy.
    Anticancer Res. 2016;36:2119-24.
    PubMed     Text format     Abstract available


  108. FIALA O, Pesek M, Finek J, Topolcan O, et al
    Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.
    Anticancer Res. 2016;36:2459-65.
    PubMed     Text format     Abstract available


  109. UGURLUER G, Chang K, Gamez ME, Arnett AL, et al
    Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
    Anticancer Res. 2016;36:2331-8.
    PubMed     Text format     Abstract available


    April 2016

  110. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    



  111. Lung Cancer and Personalized Medicine. Current Knowledge and Therapies.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    


  112. JANSSEN S, Kaesmann L, Schild SE, Rades D, et al
    Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer.
    Anticancer Res. 2016;36:1825-8.
    PubMed     Text format     Abstract available


  113. KIMURA T, Taniguchi H, Watanabe N, Saka H, et al
    Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.
    Anticancer Res. 2016;36:1767-71.
    PubMed     Text format     Abstract available


  114. KESHTGARPOUR M, Tan WS, Zwanziger J, Awadalla S, et al
    Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.
    Anticancer Res. 2016;36:1759-65.
    PubMed     Text format     Abstract available


  115. SIRIMANGKALAKITTI N, Chamni S, Suwanborirux K, Chanvorachote P, et al
    Renieramycin M Sensitizes Anoikis-resistant H460 Lung Cancer Cells to Anoikis.
    Anticancer Res. 2016;36:1665-71.
    PubMed     Text format     Abstract available


  116. BAZIN MA, Rousseau B, Marhadour S, Tomasoni C, et al
    Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines.
    Anticancer Res. 2016;36:1621-30.
    PubMed     Text format     Abstract available


  117. TADOKORO A, Kanaji N, Liu D, Yokomise H, et al
    Vimentin Regulates Invasiveness and Is a Poor Prognostic Marker in Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:1545-51.
    PubMed     Text format     Abstract available


  118. GEBAUER F, Wicklein D, Tachezy M, Grob T, et al
    Establishment and Characterization of a Pair of Patient-derived Human Non-small Cell Lung Cancer Cell Lines from a Primary Tumor and Corresponding Lymph Node Metastasis.
    Anticancer Res. 2016;36:1507-18.
    PubMed     Text format     Abstract available


  119. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  120. NISMAN B, Appelbaum L, Yutkin V, Nechushtan H, et al
    Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.
    Anticancer Res. 2016;36:1791-7.
    PubMed     Text format     Abstract available


    March 2016
  121. KASMANN L, Janssen S, Schild SE, Rades D, et al
    Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer.
    Anticancer Res. 2016;36:1089-91.
    PubMed     Text format     Abstract available


  122. OWEN S, Gao Y, Zhi X, Wei C, et al
    Effect of YangZheng XiaoJi Extract, DME-25, on Endothelial Cells and their Response to Avastin.
    Anticancer Res. 2016;36:1181-92.
    PubMed     Text format     Abstract available


  123. SVATON M, Fiala O, Pesek M, Bortlicek Z, et al
    The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
    Anticancer Res. 2016;36:1077-82.
    PubMed     Text format     Abstract available


  124. KATO K, Gemba K, Fujimoto N, Aoe K, et al
    Computed Tomographic Features of Malignant Peritoneal Mesothelioma.
    Anticancer Res. 2016;36:1067-72.
    PubMed     Text format     Abstract available


    February 2016
  125. JANSSEN S, Kasmann L, Rudat V, Rades D, et al
    Stereotactic Body Radiation Therapy (SBRT) for Recurrent Non-small Cell Lung Cancer (NSCLC).
    Anticancer Res. 2016;36:825-8.
    PubMed     Text format     Abstract available


  126. KASMANN L, Janssen S, Schild SE, Rades D, et al
    Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer.
    Anticancer Res. 2016;36:803-5.
    PubMed     Text format     Abstract available


  127. YOSHIYAMA A, Morii T, Ohtsuka K, Ohnishi H, et al
    Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
    Anticancer Res. 2016;36:625-31.
    PubMed     Text format     Abstract available


  128. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


    January 2016
  129. SHI R, Diaz R, Shi Z, Duvall E, et al
    The Effect of Payer Status on Survival of Patients with Stage I/II Non-small Cell Lung Cancer: NCDB 1998-2011.
    Anticancer Res. 2016;36:319-26.
    PubMed     Text format     Abstract available


  130. KUBOTA T, Okano Y, Sakai M, Takaoka M, et al
    Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:307-12.
    PubMed     Text format     Abstract available


  131. PARK HJ, Oh JS, Chang JW, Hwang SG, et al
    Proton Irradiation Sensitizes Radioresistant Non-small Cell Lung Cancer Cells by Modulating Epidermal Growth Factor Receptor-mediated DNA Repair.
    Anticancer Res. 2016;36:205-12.
    PubMed     Text format     Abstract available


  132. LAI CY, Chang WS, Hsieh YH, Hsu CM, et al
    Association of Tissue Inhibitor of Metalloproteinase-1 Genotypes with Lung Cancer Risk in Taiwan.
    Anticancer Res. 2016;36:155-160.
    PubMed     Text format     Abstract available


  133. CHIKAISHI Y, Uramoto H, Koyanagi Y, Yamada S, et al
    TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer.
    Anticancer Res. 2016;36:121-7.
    PubMed     Text format     Abstract available


  134. KIMURA Y, Sumiyoshi M, Baba K
    Antitumor and Antimetastatic Activity of Synthetic Hydroxystilbenes Through Inhibition of Lymphangiogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages.
    Anticancer Res. 2016;36:137-48.
    PubMed     Text format     Abstract available


  135. LUMACHI F, Chiara GB, Tozzoli R, Del Contea A, et al
    Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis.
    Anticancer Res. 2016;36:13-9.
    PubMed     Text format     Abstract available


  136. DEVINE A, Marignol L
    Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis.
    Anticancer Res. 2016;36:5-12.
    PubMed     Text format     Abstract available


  137. FIALA O, Pesek M, Finek J, Svaton M, et al
    Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.
    Anticancer Res. 2016;36:461-6.
    PubMed     Text format     Abstract available


  138. FIALA O, Pesek M, Finek J, Minarik M, et al
    Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2016;36:455-60.
    PubMed     Text format     Abstract available


  139. FIALA O, Pesek M, Finek J, Svaton M, et al
    Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.
    Anticancer Res. 2016;36:447-53.
    PubMed     Text format     Abstract available


    December 2015
  140. SPAKS A, Jaunalksne I, Spaka I, Chudasama D, et al
    Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer.
    Anticancer Res. 2015;35:6979-83.
    PubMed     Text format     Abstract available


  141. WATANABE S, Inoue A, Nukiwa T, Kobayashi K, et al
    Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
    Anticancer Res. 2015;35:6957-61.
    PubMed     Text format     Abstract available


  142. ALBERTS L, El Sharouni SY, Hofman FN, VAN Putte BP, et al
    Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts.
    Anticancer Res. 2015;35:6773-9.
    PubMed     Text format     Abstract available


    November 2015
  143. GOKE A, Goke R, Ofner A, Herbst A, et al
    The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis.
    Anticancer Res. 2015;35:5873-9.
    PubMed     Text format     Abstract available


  144. YOSHIMASU T, Ohashi T, Oura S, Kokawa Y, et al
    A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents.
    Anticancer Res. 2015;35:5851-5.
    PubMed     Text format     Abstract available


  145. DEMPKE WC, Edvardsen K, Lu S, Reinmuth N, et al
    Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Anticancer Res. 2015;35:5797-806.
    PubMed     Text format     Abstract available


  146. DEMPKE WC, Sellmann L, Fenchel K, Edvardsen K, et al
    Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Anticancer Res. 2015;35:5745-57.
    PubMed     Text format     Abstract available


  147. GALLO K, Brickman A, Warren WH, Gattuso P, et al
    Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma.
    Anticancer Res. 2015;35:6325-7.
    PubMed     Text format     Abstract available


  148. MICHELSEN L, Sorensen JB
    Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Anticancer Res. 2015;35:6255-9.
    PubMed     Text format     Abstract available


  149. ANDERSEN M, Trapani D, Ravn J, Sorensen JB, et al
    Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Anticancer Res. 2015;35:6223-9.
    PubMed     Text format     Abstract available


  150. KLAIRMONT M, Kopkash K, Favuzza J, Hill M, et al
    Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus.
    Anticancer Res. 2015;35:6159-62.
    PubMed     Text format     Abstract available


    October 2015
  151. KASTELIJN EA, El Sharouni SY, Hofman FN, Van Putte BP, et al
    Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.
    Anticancer Res. 2015;35:5607-14.
    PubMed     Text format     Abstract available


  152. FRAKULLI R, Salvi F, Balestrini D, Parisi A, et al
    Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas.
    Anticancer Res. 2015;35:5581-6.
    PubMed     Text format     Abstract available


  153. WIEGAND S, Zimmermann A, Wilhelm T, Werner JA, et al
    Survival After Distant Metastasis in Head and Neck Cancer.
    Anticancer Res. 2015;35:5499-502.
    PubMed     Text format     Abstract available


  154. VETVICKA V, Vetvickova J
    Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells.
    Anticancer Res. 2015;35:5287-92.
    PubMed     Text format     Abstract available


  155. KUNII E, Ozasa H, Oguri T, Maeno K, et al
    Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.
    Anticancer Res. 2015;35:5241-7.
    PubMed     Text format     Abstract available


  156. FERGUSON DM, Jacobson BA, Jay-Dixon J, Patel MR, et al
    Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
    Anticancer Res. 2015;35:5211-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: